RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals “To the extent you’re able then to shift the development program toward a biologic embodiment of the biology you’re trying to exploit,” Richard Pops, chairman and CEO of biopharma Alkermes, said, “that’s probably worth on the order of twice as much as doing it in a small molecule.”
The IRA does include a provision exempting single-indication orphan drugs, plasma-based drugs and low–Medicare spend drugs from price negotiations. For Katie Cumnock, research lead at California-based healthcare investment firm Patient Square Capital, this will reinforce and accelerate existing trends in drug development.
“We’re already thinking about orphan and rare diseases," Cumnock said during the panel discussion." We’re already pursuing some of the more innovative technologies and techniques like cell and gene therapy, which may be subject to some of the exclusions of this act and may, in fact, become more valuable as time goes on."